Brian Piper Net Worth

The estimated Net Worth of Brian Piper is at least $41.7 mil dollars as of 25 August 2021. Brian Piper owns over 8,333 units of Prelude Therapeutics Inc stock worth over $41,665 and over the last 8 years Brian sold PRLD stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Brian Piper PRLD stock SEC Form 4 insiders trading

Brian has made over 2 trades of the Prelude Therapeutics Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently Brian exercised 8,333 units of PRLD stock worth $15,749 on 25 August 2021.

The largest trade Brian's ever made was exercising 8,333 units of Prelude Therapeutics Inc stock on 25 August 2021 worth over $15,749. On average, Brian trades about 2,381 units every 13 days since 2017. As of 25 August 2021 Brian still owns at least 8,333 units of Prelude Therapeutics Inc stock.

You can see the complete history of Brian Piper stock trades at the bottom of the page.

What's Brian Piper's mailing address?

Brian's mailing address filed with the SEC is C/O PRELUDE THERAPEUTICS INCORPORATED, 200 POWDER MILL ROAD, WILMINGTON, DE, 19803.

Insiders trading at Prelude Therapeutics Inc

Over the last 5 years, insiders at Prelude Therapeutics Inc have traded over $822,895 worth of Prelude Therapeutics Inc stock and bought 5,875,215 units worth $87,687,261 . The most active insiders traders include Bros. Advisors Lp667, L.P.B..., David P Bonita, eAdvisors Llc Orbi Med Capit.... On average, Prelude Therapeutics Inc executives and independent directors trade stock every 30 days with the average trade being worth of $608,735. The most recent stock trade was executed by Jane Huang on 4 July 2024, trading 9,375 units of PRLD stock currently worth $46,875.

What does Prelude Therapeutics Inc do?

Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of small molecule therapies optimized to target the key driver mechanisms in cancers. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies in patients who are refractory to or intolerant of established therapies; and PRT811, which is in Phase 1 clinical trials in solid tumors, including glioblastoma multiforme and primary central nervous system lymphomas. The company is also developing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a potent inhibitor of CDK9 that exhibits high kinome selectivity; PRT-SCA2, which is in preclinical stage for multiple genomically selected cancers; and PRT-K4 that is in preclinical stage for solid tumors. Prelude Therapeutics Incorporated was incorporated in 2016 and is headquartered in Wilmington, Delaware.

Complete history of Brian Piper stock trades at Prelude Therapeutics Inc

Prelude Therapeutics Inc executives and stock owners

Prelude Therapeutics Inc executives and other stock owners filed with the SEC include:

• Dr. Krishna Vaddi D.V.M., Ph.D.,
  Founder, CEO & Director
• Dr. Deborah Morosini,
  Exec. VP & Chief of Clinical Affairs
• Naveen Babbar,
  Sr. VP of Translation Medicine
• Dr. Madhu Pudipeddi Ph.D.,
  Sr. VP of Technical Operations
• Dr. Andrew P. Combs Ph.D.,
  Exec. VP & Head of Chemistry
• Michele Porreca,
  Chief People Officer
• Dr. Peggy A. Scherle Ph.D.,
  Chief Scientific Officer
• Laurent Chardonnet,
  Chief Financial Officer
• David P Bonita,
  
• Martin Babler,
  
• Bros. Advisors Lp667, L.P.B...,
  
• Christopher Pierce,
  EVP and Chief of Business Oper
• Deborah Morosini,
  EVP, Chief of Clinical Affairs
• Advisors Llc Orbi Med Capit...,
  
• Paul A Friedman,
  
• Krishna Vaddi,
  CEO
• David J Mauro,
  Chief Medical Officer
• Brian Piper,
  Chief Financial Officer
• Laurent Chardonnet,
  Chief Financial Officer
• Jane Huang,
  President, CMO
• Peggy Scherle,
  Chief Scientific Officer
• Bryant David Lim,
  CLO, Interim CFO, Corp Sec.
• Bros. Advisors Lp667, L.P.B...,
  
• Victor Sandor,
  
• Mardi Dier,